High-throughput gene expression and mutation profiling: Current methods and future perspectives

Breast Care

Volumn 8, Issue 6, 2013, Pages 401-406

  Karn, Thomas ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Breast cancer, molecular subtypes; Cancer genome; Gene expression profiling; Next generation sequencing; Tumor heterogeneity

Indexed keywords

BREAST CANCER; CANCER GENETICS; CANCER RESEARCH; COPY NUMBER VARIATION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; REVIEW; TUMOR GENE; ARTICLE; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; DNA METHYLATION; DNA SEQUENCE; ENZYME ACTIVITY; EPIGENETICS; EXOME; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; GENETIC PREDISPOSITION; METABOLOMICS; MISSENSE MUTATION; MUTATION RATE; NEXT GENERATION SEQUENCING; PHARMACOGENOMICS; PROTEOMICS; RNA SPLICING; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR CLASSIFICATION;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA;

EID: 84892382278     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000357461     Document Type: Review

References (60)

1. Green ED, Guyer MS, Manolio TA, et al.: Charting a course for genomic medicine from base pairs to bedside. Nature 2011;470: 204-213.
2. Simon R, Radmacher MD, Dobbin K, et al.: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003;95: 14-18.
3. Ioannidis JPA, Khoury MJ: Improving validation practices in 'omics' research. Science 2011;334: 1230-1232.
4. Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 2009;360: 790-800.
5. Reis-Filho JS, Pusztai L: Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011;378: 1812-1823.
6. Kaufmann M, Pusztai L: Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer 2011;117: 1575-1582.
7. Prat A, Ellis MJ, Perou CM: Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 2012;9: 48-57.
8. van,t Veer LJ, Dai H, van de Vijver MJ, et al.: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415: 530-536.
9. Ahr A, Karn T, Solbach C, et al.: Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002;359: 131-132.
10. van de Vijver MJ, He YD, van't Veer LJ, et al.R: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999- 2009.
11. Perou CM, Sørlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
12. Sørlie T, Perou CM, Tibshirani R, et al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98: 10869-10874.
13. Rouzier R, Perou CM, Symmans WF, et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11: 5678-5685.
14. Rody A, Karn T, Solbach C, et al.: The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast 2007;16: 235-240.
15. von Minckwitz G, Untch M, Blohmer J, et al.: Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30: 1796-1804.
16. Prat A, Parker JS, Karginova O, et al.: Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010;12:R68.
17. Rody A, Karn T, Liedtke C, et al.: A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res 2011;13:R97.
18. Lehmann BD, Bauer JA, Chen X, et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121: 2750-2767.
19. Azim HA, Michiels S, Zagouri F, et al.: Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement. Ann Oncol 2013;24: 647-654.
20. Teschendorff AE, Miremadi A, Pinder SE, et al.: An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
21. Schmidt M, Böhm D, von Törne C, et al.: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008; 68: 5405-5413.
22. Rody A, Holtrich U, Pusztai L, et al.: T-cell metagene predicts a favorable prognosis in estrogen receptor- negative and HER2-positive breast cancers. Breast Cancer Res 2009;11:R15.
23. Bianchini G, Qi Y, Alvarez RH, et al.: Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010;28: 4316-4323.
24. Denkert C, Loibl S, Noske A, et al.: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28: 105-113.
25. Chung CC, Chanock SJ: Current status of genomewide association studies in cancer. Hum Genet 2011;130: 59-78.
26. Hindorff LA, Gillanders EM, Manolio TA: Genetic architecture of cancer and other complex diseases: Lessons learned and future directions. Carcinogenesis 2011;32: 945-954.
27. Desmedt C, Voet T, Sotiriou C, et al.: Next-generation sequencing in breast cancer: First take home messages. Curr Opin Oncol 2012;24: 597-604.
28. Shah SP, Morin RD, Khattra J, et al.: Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;461:809- 813.
29. Ding L, Ellis MJ, Li S, et al.: Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464: 999-1005.
30. Garraway LA, Lander ES: Lessons from the cancer genome. Cell 2013;153: 17-37.
31. Wetterstrand KA: DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). http://www.genome.gov/sequencingcosts/. Accessed 2 September 2013.
32. Dawson S, Rueda OM, Aparicio S, et al.: A new genome-driven integrated classification of breast cancer and its implications. EMBO J 2013;32:617- 628.
33. Bozic I, Antal T, Ohtsuki H, et al.: Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 2010;107: 18545-18550.
34. Vogelstein B, Papadopoulos N, Velculescu VE, et al.: Cancer genome landscapes. Science 2013;339: 1546-1558.
35. Shibata D: Cancer. Heterogeneity and tumor history. Science 2012;336: 304-305.
36. Jones S, Chen W, Parmigiani G, et al.: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA 2008;105:4283- 4288.
37. Lawrence MS, Stojanov P, Polak P, et al.: Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214- 218.
38. Steensma DP: The beginning of the end of the beginning in cancer genomics. N Engl J Med 2013; 368: 2138-2140.
39. Curtis C, Shah SP, Chin S, et al.: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486: 346-352.
40. Koboldt DC, Fulton RS, McLellan MD, et al.: Comprehensive molecular portraits of human breast tumours. Nature 2012;490: 61-70.
41. Iyer G, Hanrahan AJ, Milowsky MI, et al.: Genome sequencing identifies a basis for everolimus sensitivity. Science 2012;338:221.
42. Corless CL: Medicine. Personalized cancer diagnostics. Science 2011;334: 1217-1218.
43. Aparicio S, Caldas C: The implications of clonal genome evolution for cancer medicine. N Engl J Med 2013;368: 842-851.
44. Gray J, Druker B: Genomics: The breast cancer landscape. Nature 2012;486: 328-329.
45. Ellis MJ, Ding L, Shen D, et al.: Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486: 353-360.
46. Shah SP, Roth A, Goya R, et al.: The clonal and mutational evolution spectrum of primary triplenegative breast cancers. Nature 2012;486: 395-399.
47. Stephens PJ, Tarpey PS, Davies H, et al.: The landscape of cancer genes and mutational processes in breast cancer. Nature 2012;486: 400-404.
48. Hanahan D, Weinberg RA: Hallmarks of cancer: The next generation. Cell 2011;144: 646-674.
49. Landau DA, Carter SL, Stojanov P, et al.: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152: 714-726.
50. Nik-Zainal S, van Loo P, Wedge DC, et al.: The life history of 21 breast cancers. Cell 2012;149: 994-1007.
51. Yachida S, Jones S, Bozic I, et al.: Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467: 1114-1117.
52. Gerlinger M, Rowan AJ, Horswell S, et al.: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366: 883-892.
53. Diaz LA, Williams RT, Wu J, et al.: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486: 537-540.
54. Yap TA, Gerlinger M, Futreal PA, et al.: Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012;4:127ps10.
55. Alexandrov LB, Nik-Zainal S, Wedge DC, et al.: Signatures of mutational processes in human cancer. Nature 2013;500: 415-421.
56. Nik-Zainal S, Alexandrov LB, Wedge DC, et al.: Mutational processes molding the genomes of 21 breast cancers. Cell 2012;149: 979-993.
57. Stephens PJ, Greenman CD, Fu B, et al.: Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011;144: 27-40.
58. Banerji S, Cibulskis K, Rangel-Escareno C, et al.: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012;486: 405-409.
59. Loman NJ, Misra RV, Dallman TJ, et al.: Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012;30:562.
60. Leary RJ, Kinde I, Diehl F, et al.: Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010;2:20ra14.